High Resolution Melting Analysis for Epidermal Growth Factor Receptor Mutations in Formalin-fixed Paraffin-embedded Tissue and Plasma Free DNA from Non-small Cell Lung Cancer Patients |
Jing, Chang-Wen
(Clinical Cancer Research Center, Jiangsu Cancer Hospical)
Wang, Zhuo (Clinical Cancer Research Center, Jiangsu Cancer Hospical) Cao, Hai-Xia (Department of Epidemiology, Jiangsu Cancer Hospical) Ma, Rong (Clinical Cancer Research Center, Jiangsu Cancer Hospical) Wu, Jian-Zhong (Clinical Cancer Research Center, Jiangsu Cancer Hospical) |
1 | Do H, Krypuy M, Mitchell PL, et al (2008). High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer, 8, 142. DOI ScienceOn |
2 | Goto K, Ichinose Y, Ohe Y, et al (2012). Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol, 7, 115-21. DOI |
3 | Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. DOI ScienceOn |
4 | Hu C, Liu X, Chen Y, et al (2012). Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncol Rep, 28, 1815-21. DOI |
5 | Jian G, Songwen Z, Ling Z, et al (2010). Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol, 136, 1341-7. DOI ScienceOn |
6 | Jiang B, Liu F, Yang L, et al (2011). Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res, 39, 1392-401. DOI |
7 | Kim HR, Lee SY, Hyun DS, et al (2013). Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res, 32, 50. DOI ScienceOn |
8 | Kimura H, Kasahara K, Kawaishi M, et al (2006a). Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res, 12, 3915-21. DOI ScienceOn |
9 | Kimura H, Kasahara K, Shibata K, et al (2006b). EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol, 1, 260-7. DOI |
10 | Krypuy M, Ahmed AA, Etemadmoghadam D, et al (2007). High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer, 7, 168. DOI |
11 | Kuang Y, Rogers A, Yeap BY, et al (2009). Non-invasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res, 15, 2630-6. DOI ScienceOn |
12 | Mack PC, Holland WS, Burich RA, et al (2009). EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol, 4, 1466-72. DOI |
13 | Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8. DOI ScienceOn |
14 | Nomoto K, Tsuta K, Takano T, et al (2006). Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol, 126, 608-15. DOI ScienceOn |
15 | Maheswaran S, Sequist LV, Nagrath S, et al (2008). Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med, 359, 366-77. DOI ScienceOn |
16 | Mitsudomi T, Morita S, Yatabe Y, et al (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 11, 121-8. DOI ScienceOn |
17 | Nicholson RI, Gee JM, Harper ME. (2001). EGFR and cancer prognosis. Eur J Cancer, 37 Suppl 4, S9-15. |
18 | Pathak AK, Bhutani M, Kumar S, et al (2006). Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem, 52, 1833-42. |
19 | Scaltriti M and Baselga J (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res, 12, 5268-72. DOI ScienceOn |
20 | Shigematsu H, Lin L, Takahashi T, et al (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 97, 339-46. DOI ScienceOn |
21 | Sozzi G, Conte D, Leon M, et al (2003). Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol, 21, 3902-8. DOI ScienceOn |
22 | Takano EA, Mitchell G, Fox S B, et al (2008). Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC Cancer, 8, 59. DOI ScienceOn |
23 | Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 12, 735-42. DOI ScienceOn |
24 | Thatcher N, Chang A, Parikh P, et al (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-37. DOI ScienceOn |
25 | Wojdacz TK, Dobrovic A (2007). Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res, 35, e41. DOI ScienceOn |
![]() |